We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Urinary Protein Excretion Increases Risk of Cognitive Decline

By LabMedica International staff writers
Posted on 23 Dec 2010
A simple urine test could identify individuals at risk from suffering from irrational behavior and confusion. More...


Albuminuria, a pathological condition where the protein albumin is excreted in the urine, and low kidney function as estimated by the glomerular filtration rate, are indicative of cognitive impairment.

In a study, carried out at Stanford University (Stanford, CA, USA), clinical data from 19,399 individuals was collected to see whether cognitive decline was associated with albuminuria and deficient renal function. A total of 1,184 participants (6.1%) developed cognitive impairment over an average follow-up of 3.8 years. Individuals with albuminuria were 1.31-1.57 times more likely to develop cognitive impairment compared to individuals without albuminuria.

This association was strongest for individuals with normal kidney function who had an estimated glomerular filtration rate (eGFR) equal to or greater than 60 mL/min/1.73 m2, but was attenuated among individuals with low levels of kidney function. Conversely, low kidney function with eGFR of less than 60 mL/min/1.73 m2, was associated with a higher risk for developing cognitive impairment only among individuals without albuminuria. Individuals with albuminuria and normal kidney function had a higher probability for developing cognitive impairment as compared to individuals with moderate reductions in kidney function with eGFR of 45-59 mL/min/1.73 m2, in the absence of albuminuria.

Manjula Kurella Tamura, MD, from Stanford University, said, "The results are important because albuminuria is easily measured and potentially modifiable. Incorporating information about albuminuria along with kidney function should help clinicians identify patients at high risk for subsequent cognitive decline and dementia." The findings indicate that the presence of protein in the urine, even in small amounts, could be a warning sign that a patient may later have difficulty thinking clearly. The study was presented orally at the annual meeting of American Society of Nephrology, held in Denver, CO, USA, November 16 – 21, 2010.

Related Links:

Stanford University




Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Electrolyte Analyzer
CBS-4000 (CBS-400)
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: The VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC assay for assessing PTEN protein in prostate adenocarcinoma, with staining performed using the OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument (Photo courtesy of Roche)

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.